Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Identification of Novel Therapeutic Targets for High-Grade Serous Ovarian Cancer

EF 2019-20

Résumé
"Ovarian cancer is the sixth leading cause of cancer related death for Canadian women. Cancers of the high-grade serous (HGSC) subtype are the most prevalent and lethal, accounting for 70-80% of all cases. Despite recent improvements in treatment, 75% of patients relapse with chemoresistance and die from this disease. Thus, there is a need for the discovery of novel therapeutics. Our lab has recently published an integrated proteomics strategy in which glycosylated peptides were enriched from tumor and sera of HGSC patient derived xenograft (PDX) models to detect novel serum biomarkers for HGSC recurrence. An unexplored facet of this study was the simultaneous enhancement of plasma membrane proteins observed in the tumor glycoproteome. Plasma membrane proteins make favourable drug targets due to their easily accessible cell surface localization and their role in important biological functions. Hence, the aim of this project is to interrogate the glycoproteome of HGSC PDX tumors to identify and functionally validate novel therapeutic target candidates. Prioritization of cell surface localization and confirmed expression in patient samples has shortlisted 386 glycoproteins from the PDX glycoproteome. Targeted CRISPR/Cas9 screens will be performed to identify which of these glycoproteins are essential for cancer cell survival. Essential candidates will then be functionally validated to investigate effects on 3D tumor growth and invasion. Functional assays will be performed in spheroid models made with HGSC cells and patient-derived cancer-associated fibroblasts to create a more clinically relevant tumor microenvironment. Ultimately, this project will systematically prioritize and evaluate candidates for novel therapeutic targets to help reduce the clinical burden of HGSC."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428828
Name
Govindarajan Meinusha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Novel Therapeutic Targets for High-Grade Serous Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Associated Fibroblasts; Cell-Surface Proteins; Crispr; Glycoproteomics; High-Grade Serous Cancer; Ovarian Cancer; Patient Derived Xenografts; Spheroids; Therapeutic Targets
Abstract
"Ovarian cancer is the sixth leading cause of cancer related death for Canadian women. Cancers of the high-grade serous (HGSC) subtype are the most prevalent and lethal, accounting for 70-80% of all cases. Despite recent improvements in treatment, 75% of patients relapse with chemoresistance and die from this disease. Thus, there is a need for the discovery of novel therapeutics. Our lab has recently published an integrated proteomics strategy in which glycosylated peptides were enriched from tumor and sera of HGSC patient derived xenograft (PDX) models to detect novel serum biomarkers for HGSC recurrence. An unexplored facet of this study was the simultaneous enhancement of plasma membrane proteins observed in the tumor glycoproteome. Plasma membrane proteins make favourable drug targets due to their easily accessible cell surface localization and their role in important biological functions. Hence, the aim of this project is to interrogate the glycoproteome of HGSC PDX tumors to identify and functionally validate novel therapeutic target candidates. Prioritization of cell surface localization and confirmed expression in patient samples has shortlisted 386 glycoproteins from the PDX glycoproteome. Targeted CRISPR/Cas9 screens will be performed to identify which of these glycoproteins are essential for cancer cell survival. Essential candidates will then be functionally validated to investigate effects on 3D tumor growth and invasion. Functional assays will be performed in spheroid models made with HGSC cells and patient-derived cancer-associated fibroblasts to create a more clinically relevant tumor microenvironment. Ultimately, this project will systematically prioritize and evaluate candidates for novel therapeutic targets to help reduce the clinical burden of HGSC."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Govindarajan, Meinusha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~